MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have received an average recommendation of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $35.00.

A number of equities analysts recently issued reports on INKT shares. Zacks Research raised shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th.

MiNK Therapeutics Price Performance

NASDAQ INKT opened at $11.28 on Friday. The stock has a market capitalization of $52.88 million, a price-to-earnings ratio of -3.72 and a beta of 0.34. MiNK Therapeutics has a 1-year low of $6.34 and a 1-year high of $76.00. The business’s fifty day moving average price is $11.88 and its 200-day moving average price is $13.19.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. Equities research analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC raised its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. 2.87% of the stock is currently owned by hedge funds and other institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.